Physician profile
Khalid Mahmood
NPI 1164464152
$4,173.43
in general payments reported to CMS, 2019-2025
59 companies · $1,300 in 2025
The $1,300 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $79.67 · 2021: $11.92 · 2022: $968 · 2023: $909 · 2024: $770 · 2025: $1,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,959 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,959.39 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $426.62 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $262.57 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Eisai INC. | $177.77 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $174.72 | 2022-2025 | Opdivo |
| Glaxosmithkline, LLC. | $172.30 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Genzyme Corporation | $171.20 | 2022-2025 | |
| Sobi, INC | $162.55 | 2022-2024 | |
| Janssen Biotech, INC. | $159.99 | 2022-2025 | Rybrevant, Talvey, Imbruvica |
| Gilead Sciences, INC. | $135.48 | 2021-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $129.34 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $124.05 | 2019-2025 | Imfinzi |
| Celgene Corporation | $120.83 | 2022-2025 | Reblozyl, Breyanzi |
| Pfizer INC. | $110.60 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $104.16 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Mirati Therapeutics, INC. | $91.81 | 2023-2024 | Krazati |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $87.14 | 2022-2025 | Itovebi, Venclexta, Phesgo |
| Incyte Corporation | $82.67 | 2022-2025 | Jakafi, Niktimvo, Monjuvi |
| Abbvie INC. | $82.59 | 2022-2025 | |
| Exelixis INC. | $77.34 | 2022-2025 | Cabometyx |
| Lilly USA, LLC | $73.15 | 2022-2023 | Retevmo, Verzenio, Jaypirca |
| Tempus Ai, INC | $67.43 | 2024 | |
| Jazz Pharmaceuticals INC. | $61.86 | 2022-2024 | |
| Pharmaessentia USA Corporation | $60.52 | 2022-2024 | Besremi |
| Regeneron Healthcare Solutions, INC. | $58.40 | 2023-2025 | Libtayo, Lynozyfic |
| Daiichi Sankyo INC. | $58.29 | 2025 | Vanflyta, Enhertu |
| Tersera Therapeutics LLC | $58.28 | 2024-2025 | Zoladex |
| Takeda Pharmaceuticals U.S.A., INC. | $54.33 | 2019-2023 | Alunbrig |
| Adc Therapeutics America, INC. | $52.88 | 2025 | |
| Pharmacosmos Therapeutics INC. | $51.37 | 2023 | Monoferric |
| Array Biopharma INC | $47.77 | 2024 | Lorbrena, Braftovi, Mektovi |
| Seagen INC. | $42.46 | 2023 | Adcetris, Padcev |
| Stemline Therapeutics INC. | $39.17 | 2023-2024 | Orserdu |
| Emd Serono, INC. | $38.71 | 2023-2025 | Bavencio |
| Madrigal Pharmaceuticals | $34.70 | 2025 | Rezdiffra |
| Cti Biopharma Corp. | $32.99 | 2022-2023 | Vonjo |
| Syndax Pharmaceuticals, INC. | $31.78 | 2025 | |
| Adaptive Biotechnologies Corporation | $30.64 | 2022-2023 | Clonoseq |
| Pharmacyclics LLC, An Abbvie Company | $27.32 | 2022 | |
| Springworks Therapeutics, INC. | $25.18 | 2025 | Gomekli |
| Genmab U.S., INC. | $23.81 | 2025 | Epkinly |
| Karyopharm Therapeutics INC. | $23.06 | 2022 | |
| Aveo Pharmaceuticals, INC. | $22.05 | 2024 | |
| Apellis Pharmaceuticals, INC. | $21.99 | 2022 | |
| Tolmar, INC. | $20.74 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $20.74 | 2025 | Rubraca |
| Ipsen Biopharmaceuticals, INC | $20.48 | 2025 | Onivyde |
| Mylan Institutional INC. | $19.45 | 2023 | Ogivri, Fulphila |
| Blueprint Medicines Corporation | $19.39 | 2022 | |
| Taiho Oncology, INC. | $19.31 | 2025 | |
| Tactile Systems Technology INC | $19.19 | 2022 | |
| Sumitomo Pharma America, INC. | $19.06 | 2023 | Orgovyx |
| Agios Pharmaceuticals, INC. | $17.56 | 2025 | Pyrukynd |
| Recordati_rare_diseases_inc. | $17.21 | 2025 | Enjaymo |
| Sirtex Medical INC | $16.64 | 2025 | Sir-Spheres Microspheres |
| Biogen, INC. | $15.93 | 2019 | |
| Amgen INC. | $15.93 | 2022 | |
| Sun Pharmaceutical Industries INC. | $14.25 | 2023 | Odomzo, Yonsa |
| Morphosys, US INC. | $14.01 | 2023 | Monjuvi |
| Fortovia Therapeutics, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Mahmood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.